SUNNYVALE, Calif. - Intuitive (NASDAQ:ISRG) announced Wednesday the promotion of Taylor Patton to Chief Commercial and Marketing Officer, effective July 1.
Patton, currently Global Senior Vice President of the company’s endoluminal business, will succeed Henry Charlton, who will transition to Senior Vice President of Global Business Operations. The changes were disclosed in a press release statement.
Patton has worked at Intuitive for nearly two decades, holding positions across commercial, marketing, and clinical application engineering. In his current role, he led the global launch of the company’s Ion platform, which involved establishing commercial organizations and clinical programs across multiple geographies.
"Taylor has spent nearly two decades with Intuitive, building and scaling teams across multiple business units and geographies," said CEO Dave Rosa in the statement.
Charlton joined Intuitive in 2003 and has served as Chief Commercial and Marketing Officer. In his new role, he will focus on global business operations and customer support.
Intuitive manufactures the da Vinci surgical system and the Ion endoluminal system. The company is based in Sunnyvale, California, and specializes in minimally invasive care technology. With a market capitalization of $150 billion, Intuitive stands as a prominent player in the Healthcare Equipment & Supplies industry, according to InvestingPro analysis, which rates the company’s overall financial health as "GREAT."
Patton will join Intuitive’s Executive Leadership team as part of the promotion. The company stated that Charlton will work with Patton to support the transition.
The leadership changes come as the company continues its commercial operations globally. According to the statement, Intuitive’s technologies have enabled physicians to serve over 20 million patients. The company reported revenue of $10.6 billion with a 21% growth rate over the last twelve months. While the stock has declined 26% year-to-date, InvestingPro analysis suggests the shares are currently undervalued. Investors seeking deeper insights can access a comprehensive Pro Research Report on ISRG, one of 1,400+ available reports transforming complex data into actionable intelligence.
In other recent news, Intuitive Surgical announced updates to its da Vinci 5 robotic surgical system, enhancing its capabilities with over 100 improvements. These updates will be available to U.S. users starting in June, with global availability pending regulatory clearances. The enhancements include improvements to Intuitive Telepresence, allowing remote observation of procedures, and the addition of a camera for full operating room visibility.
Intuitive Surgical’s recent quarterly results have also drawn attention from analysts. The company reported revenue and earnings per share that exceeded expectations by approximately 6% and 18%, respectively. Year-over-year growth was notable, with sales increasing by 23% and earnings per share by 38%. Following these results, RBC Capital reiterated its Outperform rating with a $650 price target.
However, Piper Sandler and Barclays adjusted their price targets for Intuitive Surgical, lowering them to $580 and $651, respectively, while maintaining an Overweight rating. Both firms cited strong performance in procedures and system sales as key factors in their analyses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for ISRG plus thousands of other stocks and find your next hidden gem with massive upside.